2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
This guideline cites 19 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2021
- Source
- Lawton JS, Tamis-Holland JE, et al. Circulation. 2022;145(3):e18–e114.doi 10.1161/CIR.0000000000001038
This is the guideline where the US and Europe visibly part company. Reading ISCHEMIA and the contemporary trial data strictly, the writing committee reduced CABG for survival in three-vessel disease with preserved ejection fraction to Class 2b ('may be reasonable') — the ESC/EACTS 2018 document still gives CABG a Class I in that setting — and the demotion was contentious enough that the surgical societies withheld their endorsement. Left main disease runs the other way: PCI is 2a in anatomically low-to-medium-complexity left main, where ESC/EACTS grants Class I at SYNTAX ≤22. Both agree on radial access, on the radial artery as the second conduit and on staged complete revascularisation in STEMI. The register's revascularisation trials are grouped below.
PCI vs. CABG: multivessel & left main disease5
- 2016EXCELCardiology · Coronary · left main PCIIn 1,905 patients with left main disease of low-to-intermediate complexity, PCI with everolimus-eluting stents was non-inferior for 3-year death, stroke, or MI compared with CABG.15.4% vs 14.7%Read →
- 2016NOBLECardiology · Coronary · left main PCIIn 1,201 patients with unprotected left main coronary disease, PCI with drug-eluting stents increased 5-year death, MI, repeat revascularisation, or stroke compared with CABG.HR 1.4895% CI 1.11-1.96Read →
- 2016STICHCardiology · HF · CABGIn 1,212 patients with ischaemic cardiomyopathy (EF ≤ 35%) and CAD, coronary-artery bypass grafting plus medical therapy reduced 10-year all-cause mortality compared with medical therapy alone.HR 0.8495% CI 0.73-0.97Read →
- 2012FREEDOM 2012Cardiology · Coronary · PCI vs CABGIn 1,900 patients with diabetes and multivessel coronary disease, PCI with drug-eluting stents increased death, nonfatal MI, or nonfatal stroke compared with CABG.26.6% vs 18.7%Read →
- 2009SYNTAX CoreCardiology · Coronary · PCI vs CABGIn 1,800 patients with 3-vessel or left main coronary disease, PCI with paclitaxel-eluting stents increased 12-month death, stroke, MI, or repeat revascularisation compared with CABG.17.8% vs 12.4%Read →
Revascularisation vs. medical therapy3
- 2020ISCHEMIA CoreCardiology · Coronary · RevascularisationIn 5,179 patients with stable CAD and moderate-to-severe ischaemia, an initial invasive strategy did not reduce CV death, MI, hospitalisation for unstable angina, HF or resuscitated arrest compared with an initial conservative strategy.HR 0.93Read →
- 2018ORBITACardiology · Coronary · RevascularisationIn 200 patients with stable single-vessel angina, PCI did not improve exercise time at 6 weeks compared with a sham procedure.Read →
- 2007COURAGECardiology · Coronary · RevascularisationIn 2,287 patients with stable coronary artery disease, PCI added to optimal medical therapy did not reduce death or non-fatal MI compared with optimal medical therapy alone.HR 1.05Read →
Physiology-guided PCI (FFR)2
- 2012FAME 2Cardiology · Coronary · FFR-guided PCIIn 888 patients with stable coronary disease and a functionally significant (FFR ≤0.80) stenosis, FFR-guided PCI plus medical therapy reduced death, MI, or urgent revascularisation compared with medical therapy alone.HR 0.3295% CI 0.19-0.53Read →
- 2009FAMECardiology · Coronary · RevascularisationIn 1,005 patients with multivessel CAD, FFR-guided PCI reduced MACE at one year versus angiography-guided PCI.13.2% vs 18.3%Read →
Revascularisation in acute coronary syndromes3
- 2019COMPLETECardiology · Coronary · RevascularisationIn 4,041 STEMI patients with multivessel disease, staged complete revascularisation reduced CV death or MI compared with culprit-lesion-only PCI.HR 0.74Read →
- 2017CULPRIT-SHOCK CoreICU · CS / MCS · RevascularisationIn 706 patients with multivessel disease and cardiogenic shock, culprit-only PCI with staged completion reduced 30-day death or RRT compared with immediate multivessel PCI.RR 0.83Read →
- 2001TACTICS-TIMI 18Cardiology · Coronary · early invasive strategyIn 2,220 patients with NSTE-ACS treated with tirofiban, an early invasive strategy reduced 6-month death, MI, or rehospitalisation for ACS compared with a conservative strategy.OR 0.7895% CI 0.62-0.97Read →
Antiplatelet therapy after revascularisation6
- 2019ISAR-REACT 5Cardiology · Coronary · AntiplateletsIn 4,018 patients with acute coronary syndromes managed invasively, prasugrel reduced death, MI or stroke at one year compared with ticagrelor.HR 1.36Read →
- 2019AUGUSTUS CoreCardiology · Thrombosis · AF + PCIIn 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.Read →
- 2013WOESTCardiology · Thrombosis · AF + PCIIn 573 patients on oral anticoagulation undergoing PCI, clopidogrel without aspirin reduced bleeding compared with triple therapy.HR 0.36Read →
- 2009PLATO CoreCardiology · Coronary · AntiplateletsIn 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.HR 0.84Read →
- 2007TRITON-TIMI 38Cardiology · Coronary · AntiplateletsIn 13,608 ACS patients undergoing planned PCI, prasugrel reduced ischaemic events but increased major bleeding relative to clopidogrel.HR 0.81Read →
- 2001CURE CoreCardiology · Coronary · AntiplateletsIn 12,562 patients with NSTE-ACS, clopidogrel plus aspirin reduced the composite of CV death, MI or stroke versus aspirin alone.RR 0.8Read →
Published since the guideline3
- 2023ORBITA-2Cardiology · Coronary · RevascularisationIn 301 patients with stable angina on no antianginal medication, PCI improved the angina symptom score compared with a placebo procedure.OR 2.21Read →
- 2022FAME 3Cardiology · Coronary · FFR-guided PCIIn 1,500 patients with 3-vessel coronary disease, FFR-guided PCI did not prove non-inferior for 1-year death, MI, stroke, or repeat revascularisation compared with CABG.HR 1.595% CI 1.1-2.2Read →
- 2022REVIVED-BCIS2Cardiology · Coronary · PCI vs OMTIn 700 patients with ischaemic LV dysfunction (LVEF ≤35%) and viable myocardium, PCI plus optimal medical therapy did not reduce all-cause death or HF hospitalisation compared with optimal medical therapy alone.HR 0.9995% CI 0.78-1.27Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2011PRECOMBAT
PCI vs. CABG in unprotected left main disease.
- 2018ART (Arterial Revascularization Trial)
Bilateral vs. single internal thoracic artery grafting.
- 2018RADIAL pooled analysis
Radial artery over saphenous vein as the second conduit.
- 2009BARI 2D
Revascularisation vs. medical therapy in type 2 diabetes.
- 2013PRAMI
Preventive PCI of non-culprit lesions in STEMI.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.